Q Yin1, S-C Hung2, W K Rathmell3, L Shen4, L Wang5, W Lin5, J R Fielding6, A H Khandani5, M E Woods7, M I Milowsky8, S A Brooks9, E M Wallen10, D Shen11. 1. Information Science and Technology College, Dalian Maritime University, Dalian, 116026, China; Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA. 2. Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Radiology, Taipei Veterans General Hospital, Taipei 11217, Taiwan; School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan; Department of Biomedical Imaging and Radiological Sciences, School of Biomedical Science of Engineering, National Yang-Ming University, Taipei 11221, Taiwan. 3. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA. 4. Information Science and Technology College, Dalian Maritime University, Dalian, 116026, China. 5. Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA. 6. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 7. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Urology, University of North Carolina, Chapel Hill, NC 27599, USA. 8. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Urology, University of North Carolina, Chapel Hill, NC 27599, USA. 9. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. 10. Department of Urology, University of North Carolina, Chapel Hill, NC 27599, USA. 11. Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Brain and Cognitive Engineering, Korea University, Seoul 02841, Republic of Korea. Electronic address: dgshen@med.unc.edu.
Abstract
AIM: To identify combined positron-emission tomography (PET)/magnetic resonance imaging (MRI)-based radiomics as a surrogate biomarker of intratumour disease risk for molecular subtype ccA and ccB in patients with primary clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: PET/MRI data were analysed retrospectively from eight patients. One hundred and sixty-eight radiomics features for each tumour sampling based on the regionally sampled tumours with 23 specimens were extracted. Sparse partial least squares discriminant analysis (SPLS-DA) was applied to feature screening on high-throughput radiomics features and project the selected features to low-dimensional intrinsic latent components as radiomics signatures. In addition, multilevel omics datasets were leveraged to explore the complementing information and elevate the discriminative ability. RESULTS: The correct classification rate (CCR) for molecular subtype classification by SPLS-DA using only radiomics features was 86.96% with permutation test p=7×10-4. When multi-omics datasets including mRNA, microvascular density, and clinical parameters from each specimen were combined with radiomics features to refine the model of SPLS-DA, the best CCR was 95.65% with permutation test, p<10-4; however, even in the case of generating the classification based on transcription features, which is the reference standard, there is roughly 10% classification ambiguity. Thus, this classification level (86.96-95.65%) of the proposed method represents the discriminating level that is consistent with reality. CONCLUSION: Featured with high accuracy, an integrated multi-omics model of PET/MRI-based radiomics could be the first non-invasive investigation for disease risk stratification and guidance of treatment in patients with primary ccRCC. Published by Elsevier Ltd.
AIM: To identify combined positron-emission tomography (PET)/magnetic resonance imaging (MRI)-based radiomics as a surrogate biomarker of intratumour disease risk for molecular subtype ccA and ccB in patients with primary clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: PET/MRI data were analysed retrospectively from eight patients. One hundred and sixty-eight radiomics features for each tumour sampling based on the regionally sampled tumours with 23 specimens were extracted. Sparse partial least squares discriminant analysis (SPLS-DA) was applied to feature screening on high-throughput radiomics features and project the selected features to low-dimensional intrinsic latent components as radiomics signatures. In addition, multilevel omics datasets were leveraged to explore the complementing information and elevate the discriminative ability. RESULTS: The correct classification rate (CCR) for molecular subtype classification by SPLS-DA using only radiomics features was 86.96% with permutation test p=7×10-4. When multi-omics datasets including mRNA, microvascular density, and clinical parameters from each specimen were combined with radiomics features to refine the model of SPLS-DA, the best CCR was 95.65% with permutation test, p<10-4; however, even in the case of generating the classification based on transcription features, which is the reference standard, there is roughly 10% classification ambiguity. Thus, this classification level (86.96-95.65%) of the proposed method represents the discriminating level that is consistent with reality. CONCLUSION: Featured with high accuracy, an integrated multi-omics model of PET/MRI-based radiomics could be the first non-invasive investigation for disease risk stratification and guidance of treatment in patients with primary ccRCC. Published by Elsevier Ltd.
Authors: Atul B Shinagare; Raghu Vikram; Carl Jaffe; Oguz Akin; Justin Kirby; Erich Huang; John Freymann; Nisha I Sainani; Cheryl A Sadow; Tharakeswara K Bathala; Daniel L Rubin; Aytekin Oto; Matthew T Heller; Venkateswar R Surabhi; Venkat Katabathina; Stuart G Silverman Journal: Abdom Imaging Date: 2015-08
Authors: Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell Journal: Eur Urol Date: 2014-02-25 Impact factor: 20.096
Authors: R Manara; R Y Carlier; S Righetto; V Citton; G Locatelli; F Colas; M Ermani; D P Germain; A Burlina Journal: AJNR Am J Neuroradiol Date: 2017-01-26 Impact factor: 3.825
Authors: Philippe Lambin; Emmanuel Rios-Velazquez; Ralph Leijenaar; Sara Carvalho; Ruud G P M van Stiphout; Patrick Granton; Catharina M L Zegers; Robert Gillies; Ronald Boellard; André Dekker; Hugo J W L Aerts Journal: Eur J Cancer Date: 2012-01-16 Impact factor: 9.162
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Sakshi Gulati; Pierre Martinez; Tejal Joshi; Nicolai Juul Birkbak; Claudio R Santos; Andrew J Rowan; Lisa Pickering; Martin Gore; James Larkin; Zoltan Szallasi; Paul A Bates; Charles Swanton; Marco Gerlinger Journal: Eur Urol Date: 2014-07-19 Impact factor: 20.096